Coyote’s technology platform is designed to uncover critical pathways that maintain homeostasis and create high value therapeutics for important human diseases.  By developing oral drugs that modulate specific components of these complex cellular networks, Coyote may allow cells to regain natural homeostasis, potentially stopping or reversing the symptoms of disease.

CNS-102 works through a novel mechanism of action that is distinct from other drugs designed to treat degenerative diseases. The potent neuroprotective effects of CNS-102 have been established in animal models of ALS (Lou Gehrig’s disease) Alzheimer’s disease and several ocular indications. 

Achieving balance in business and science envelops all aspects of Coyote’s activities, including the pursuit of partners and investors.